Lee Seohyun, Woo Chang Gok, Lee Hyo Jeong, Kim Kyung-Jo, Ye Byong Duk, Byeon Jeong-Sik, Myung Seung-Jae, Yang Suk-Kyun, Park Young Soo, Park Jin-Hong, Kim Jong Hoon, Lim Seok-Byung, Kim Jin Cheon, Yu Chang Sik, Yang Dong-Hoon
Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea.
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Surg Endosc. 2015 Nov;29(11):3231-8. doi: 10.1007/s00464-015-4065-5. Epub 2015 Feb 12.
The role of postoperative radiation therapy (RT) after local excision (LE) of deep submucosal invasive rectal cancer remains unclear. We evaluated the efficacy of adjuvant RT after LE of early rectal cancer with deep submucosal invasion.
We screened 227 patients who underwent transanal excision or endoscopic removal of deep submucosal invasive rectal cancer between 1992 and 2012, of which 66 did not undergo radical surgery owing to the patient's preference or poor medical conditions. Of these, 35 (53 %) underwent LE alone (LE group) and 31 (47 %) received adjuvant RT after LE (LE + RT group). Nine patients in the RT group received concurrent adjuvant chemotherapy with 5-fluorouracil. Two independent pathologists reviewed histological data.
The mean age of patients in the LE + RT and LE groups was 59.5 ± 9.6 and 55.3 ± 11.2 years, respectively. The mean follow-up duration was 78.7 ± 66.7 months in the LE + RT group and 70.5 ± 45.7 months in the LE group. Cancer eventually recurred in six patients (9.1 %; two in the LE + RT group and four in the LE group). In five of these patients, recurrence occurred within 4 years after the initial treatment. The other patient, who was in the LE group, exhibited multiple lymph node metastases at the 116-month follow-up. Kaplan-Meier estimates of recurrence-free survival at 5 years after treatment were 96.8 % in the LE + RT group and 97 % in the LE group (P = 0.657).
RT after LE of early rectal cancer with deep submucosal invasion might not improve recurrence-free survival compared with LE alone.
深黏膜下浸润性直肠癌局部切除术后辅助放疗(RT)的作用仍不明确。我们评估了早期深黏膜下浸润性直肠癌局部切除术后辅助放疗的疗效。
我们筛选了1992年至2012年间接受经肛门切除或内镜切除深黏膜下浸润性直肠癌的227例患者,其中66例因患者个人意愿或身体状况不佳未接受根治性手术。在这些患者中,35例(53%)仅接受局部切除(局部切除组),31例(47%)在局部切除后接受辅助放疗(局部切除+放疗组)。放疗组中有9例患者接受了5-氟尿嘧啶同步辅助化疗。两名独立病理学家复查了组织学数据。
局部切除+放疗组和局部切除组患者的平均年龄分别为59.5±9.6岁和55.3±11.2岁。局部切除+放疗组的平均随访时间为78.7±66.7个月,局部切除组为70.5±45.7个月。最终有6例患者(9.1%)出现癌症复发(局部切除+放疗组2例,局部切除组4例)。其中5例患者在初始治疗后4年内复发。另1例局部切除组患者在116个月随访时出现多发淋巴结转移。治疗后5年无复发生存率的Kaplan-Meier估计值在局部切除+放疗组为96.8%,在局部切除组为97%(P=0.657)。
与单纯局部切除相比,早期深黏膜下浸润性直肠癌局部切除术后放疗可能无法提高无复发生存率。